VasQ外支架装置在多中心真实世界中的动静脉瘘应用结果
这项多国回顾性研究评估了在德国、意大利和西班牙三个血管通路中心使用VasQ外支架装置创建的自体动静脉瘘(AVF)的临床结局。结果显示成熟率达91%,主要失败率9%,6、12、18个月一期通畅率均为77%,二期通畅率6个月为91%、12和18个月为85%,需透析患者成功穿刺率86%,中位穿刺时间46天。
要点
- VasQ装置创建的AVF在真实世界中成熟率91%,主要失败率9%
- 一期通畅率6/12/18个月均为77%,二期通畅率6个月91%、12/18个月85%
- 需透析患者成功穿刺率86%,中位穿刺时间46天,功能通畅率94%
核心结论
- VasQ外支架装置创建的AVF在两个最常用解剖位置的多中心真实世界中显示出良好的通畅性和功能性结局。
研究设计与样本
- 纳入前臂和上臂头静脉AVF,通过超声流量测量评估结局,分析主要失败、可用性、通畅率和干预率。
主要发现
- 评估的46例患者中,成熟率91%,主要失败率9%。
- 一期通畅率在6、12、18个月均为77%;二期通畅率6个月91%,12和18个月85%。
- 前臂AVF与上臂头静脉AVF的一期和二期通畅率无统计学差异(P > .25)。
- 需透析患者中成功穿刺率86%(32/37),中位穿刺时间46天,功能通畅率94%。
关键数值与推荐
- 成熟率91%,主要失败率9%,一期通畅率6/12/18个月均为77%,二期通畅率6个月91%、12/18个月85%。
- 成功穿刺率86%(32/37),中位穿刺时间46天,功能通畅率94%。
- 干预率0.248次/患者年。
- 前臂AVF与上臂头静脉AVF通畅率比较P > .25。
临床怎么用
- VasQ外支架装置可用于前臂和上臂头静脉AVF的创建,在真实世界条件下可获得较高的成熟率和通畅率。
- 需透析患者中位穿刺时间46天,成功穿刺率86%,功能通畅率94%,提示该装置有助于AVF的及时使用。
- 干预率较低(0.248次/患者年),可能减少维持通畅所需的额外操作。
局限性
- 仅纳入三个欧洲中心,结果可能受中心经验和患者选择影响。
- 3例随访不足4周被排除,1例失访,可能引入偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the outcomes of arteriovenous fistulae (AVF), created with VasQ external support device under standard clinical practice across three vascular access clinics. METHODS: This multinational, retrospective study evaluated prospectively collected clinical outcomes of both forearm and upper arm brachiocephalic AVF (BCAVF) created using the VasQ device. Fifty-one AVF patients were pooled from three different vascular access centers in Germany, Italy, and Spain. Postprocedure outcomes were assessed by flow measurement with ultrasound examination in all centers. Primary failure, usability, patency, and intervention rates during the study period were evaluated. RESULTS: Fifty-one VasQ devices were implanted during 37 forearm (36 radiocephalic and 1 ulnar-basilic AVF) and 14 BCAVF procedures. The study population comprised mostly males (73%) and Caucasians (82%), with a mean age of 62.5 years (range, 38-84 years) and mean body mass index of 29.2. One patient died owing to access-unrelated reasons, and one patient was lost to follow-up without AVF assessment after its creation. From the remaining 49, 3 patients had a follow-up of less than 4 weeks and were excluded from maturation, primary failure, and dialysis initiation analysis (because those factors could not be evaluated yet), leaving 46 patients in this evaluation. Maturation was achieved in 91% of patients. The primary failure rate was 9%. A primary patency rate of 77% was observed at 6, 12, and 18 months. The secondary patency rate was 91% at 6 months, and 85% at 12 months and 18 months. Both primary patency and secondary patency did not differ statistically when comparing forearm AVF with BCAVF (P > .25). Successful cannulation was achieved in 86% of patients (32/37) requiring dialysis with a median time from creation to cannulation of 46 days. Of those patients, the functional patency rate was 94%. Five patients underwent seven interventions to maintain or restore patency or functionality, with an overall rate of 0.248 interventions per patient-year. CONCLUSIONS: AVFs created with VasQ external support device demonstrated promising patency and functionality outcomes in multicentric real-world setting across the two most commonly used anatomic locations.
引用
- Shahverdyan R, Tabbi P, Mestres G, et al. Multicenter European real-world utilization of VasQ anastomotic external support device for arteriovenous fistulae. J Vasc Surg. 2021. PMID: 34314835. doi:10.1016/j.jvs.2021.07.120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。